This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Cahn, P. Articles by Ochoa, C. Search for Related Content PubMed PubMed Citation Articles by Cahn, P. Articles by Ochoa, C. Social Bookmarking                         What's this?

Tuberculosis and HIV: A Partnership Against the Most Vulnerable

Fundación Huesped, Buenos Aires, Argentina

Hector Perez, MD

Fundación Huesped, Buenos Aires, Argentina

Graciela Ben, MD

Fundación Huesped, Buenos Aires, Argentina

Claudia Ochoa, MD

Fundación Huesped, Buenos Aires, Argentina

Tuberculosis (TB) is a major cause of morbidity and mortality worldwide. Each year, there are eight million new Mycobacterium tuberculosis complex (MTB) infections and three million TB-related deaths. The catastrophic effects of TB are borne disproportionately among the most vulnerable. The HIV pandemic has further increased the burden so that the risk of TB reactivation from latency is 5 to 15 percent in HIV/TB coinfection. Tuberculosis reactivation fuels further primary infections, creating a vicious cycle of increasing infection, disease, and deaths. In addition, drug-resistant TB exacerbates this increasingly common problem.

The clinical presentations of TB in relation to HIV and HIV-associated immune deficiency are discussed from the perspective of clinical diagnosis and treatment in patient care. Tuberculosis prophylaxis, concurrent drug treatment of TB and HIV, drug interactions, and overlapping toxicities are detailed for the practitioner. Immune reconstitution inflammatory reactions are now a common phenomenon in HIV treatment, where similar reactions have been less commonly described in TB treatment in the past.

Global distributive injustices in wealth, the burden of disease, and the provision of healthcare are obvious in TB, and clearly show us that the needs of the most vulnerable populations must be met in order to address the problems.

Key Words: tuberculosis • drug interactions • immune reconstitution • TB/HIV coinfection

Journal of the International Association of Physicians in AIDS Care (JIAPAC), Vol. 2, No. 3, 106-123 (2003)
DOI: 10.1177/154510970300200303


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?